zm 241385 has been researched along with mrs 1523 in 4 studies
| Studies (zm 241385) | Trials (zm 241385) | Recent Studies (post-2010) (zm 241385) | Studies (mrs 1523) | Trials (mrs 1523) | Recent Studies (post-2010) (mrs 1523) |
|---|---|---|---|---|---|
| 401 | 3 | 124 | 42 | 0 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donegan, RK; Lieberman, RL | 1 |
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
| Corradetti, R; Latini, S; Pedata, F; Pugliese, AM | 1 |
| Auchampach, JA; Ge, ZD; Gross, GJ; Jacobson, MA; Kreckler, LM; Peart, JN; Wan, TC | 1 |
2 review(s) available for zm 241385 and mrs 1523
| Article | Year |
|---|---|
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Drug Discovery; Glaucoma; Humans; Ligands; Protein Kinase Inhibitors; rho-Associated Kinases; Sympathomimetics | 2016 |
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |
2 other study(ies) available for zm 241385 and mrs 1523
| Article | Year |
|---|---|
Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Brain Ischemia; Electric Stimulation; Excitatory Postsynaptic Potentials; Glucose; Hippocampus; Hypoxia; In Vitro Techniques; Ischemic Preconditioning; Male; Oxygen; Purinergic P1 Receptor Antagonists; Pyridines; Rats; Rats, Wistar; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A3; Receptors, Purinergic P1; Synaptic Transmission; Time Factors; Triazines; Triazoles; Xanthines | 2003 |
Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Blood Pressure; Cardiotonic Agents; Cell Degranulation; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Histamine; In Vitro Techniques; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; p-Methoxy-N-methylphenethylamine; Pyridines; Radioligand Assay; Receptor, Adenosine A3; Triazines; Triazoles | 2006 |